IPO

2026 with glowing coin and dollar sign
Pharma

PwC projects continued growth for rest of 2026, fueled by M&A

With pharma and life sciences deals surpassing $65 billion in Q1, analysts from PwC have declared the “biopharma ecosystem is back to full health.”
Kevin Dunleavy Jun 17, 2026 5:00am
mushrooms psychedelics psychedelic drugs

Psychedelics manufacturer Optimi Health set to go public in US

May 7, 2026 11:48am
IPO initial public offering
Favicon Fierce Biotech

Avalyn brings in $300M from oversized IPO

Apr 30, 2026 3:18am
Lung
Favicon Fierce Biotech

Avalyn aims for $182M IPO to fund ph. 3 trials of lung drugs

Apr 24, 2026 7:08am
IPO initial public offering
Favicon Fierce Biotech

Avalyn plans IPO to fund ph. 3 trials of inhaled lung drugs

Apr 9, 2026 4:13am
liver
Favicon Fierce Biotech

BioVie plans $20M IPO for spinout developing liver disease drug

Mar 17, 2026 5:18am